Midday Report: Sol-Gel (SLGL) Shares Up on June 23

Equities Staff  |

Sol-Gel Technologies Ltd (NASDAQ: SLGL) has climbed $0.26 (5.88%) and sits at $4.68, as of 12:02:22 est on June 23.

5,793 shares have traded hands.

The Company has decreased 12.13% over the last 5 days and shares have fallen 25.08% over the last 30 days.

Sol-Gel anticipates its next earnings on 2022-08-03.

For technical charts, analysis, and more on Sol-Gel visit the company profile.

About Sol-Gel Technologies Ltd

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.

To get more information on Sol-Gel Technologies Ltd and to follow the company's latest updates, you can visit the company's profile page here: Sol-Gel Technologies Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content